Physician profile
Robin Egan
NPI 1972955474
$1,049.34
in general payments reported to CMS, 2019-2025
14 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $58.32 · 2024: $690 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.36 |
| Education | $284.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $346.94 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $333.82 | 2023-2025 | Blu-U, Ilumya |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Genzyme Corporation | $50.96 | 2024-2025 | |
| Lilly USA, LLC | $37.05 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $33.06 | 2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $26.03 | 2024 | Dupixent |
| Organogenesis INC. | $22.06 | 2024 | Affinity |
| Janssen Biotech, INC. | $19.00 | 2024 | Tremfya |
| Amgen INC. | $17.77 | 2024 | Otezla |
| Biofrontera INC. | $17.40 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Pfizer INC. | $17.08 | 2024 | |
| Galderma Laboratories, L.P. | $14.82 | 2024 | |
| Novartis Pharmaceuticals Corporation | $13.36 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Egan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.